THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.87_2629
Abstract: to investigate the signaling pathways altered upon drug treatment. An orthotoppic PDX model was established from a MCL patient with dual resistance to ibrutinib-venetoclax. Single agent copanlisib at 6 mg/kg/2d, idelalisib at 50 mg/kg/2d, ibrutinib… read more here.
Keywords: volasertib; ibrutinib venetoclax; copanlisib; resistance ... See more keywords
Abstract 5866: Mavorixafor enhances apoptosis of tumor cells treated with ibrutinib or venetoclax in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5866
Abstract: Despite advances in therapies for B-cell lymphoma, patients may still develop resistance and often relapse. Contributing factors may include interactions between lymphoma cells (LCs) or leukemia cells and bone marrow microenvironment (BMM). Overexpression of CXCR4WT… read more here.
Keywords: cell; lcs; cell lymphoma; ibrutinib venetoclax ... See more keywords
Abstract CT166: Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct166
Abstract: Background: CAPTIVATE (NCT02910583) is a multicenter phase 2 study of first-line ibrutinib (Ibr) + venetoclax (Ven) in CLL. In the Minimal Residual Disease (MRD) cohort, pts underwent randomization to subsequent treatment based on MRD status… read more here.
Keywords: ibr; ibr ven; ibrutinib venetoclax; post randomization ... See more keywords
Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123410
Abstract: Background: Monocytes and neutrophilic granulocytes are critical for innate immunity, through recognition and phagocytosis of pathogens, and mediation of acute inflammation through secretion of pro-inflammatory cytokines. Furthermore, monocytes constitute an important link between innate and… read more here.
Keywords: function; ibrutinib venetoclax; research funding;
Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-140871
Abstract: Both as monotherapies and in combination, the Bruton's tyrosine kinase inhibitor ibrutinib and the BH3 mimetic BCL2 inhibitor venetoclax have proven to be efficacious and are now widely used treatment options for mantle cell lymphoma… read more here.
Keywords: mcl; ibrutinib; ibrutinib venetoclax; resistance ... See more keywords
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.241539
Abstract: Therapeutic options for chronic lymphocytic leukemia (CLL) patients have expanded over recent years as efficacious novel agents (NA) have received licensing approval, initially in relapsed, refractory (R/R) disease. Ibrutinib is a Bruton tyrosine kinase (BTK)… read more here.
Keywords: ibrutinib venetoclax; pfs; cll; chronic lymphocytic ... See more keywords
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.833714
Abstract: B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL). A pivotal and apical molecule in the BCR pathway is Bruton’s… read more here.
Keywords: amg 176; ibrutinib venetoclax; therapy; venetoclax ... See more keywords